The surgical implications of estrophile protein estimations in carcinoma of the breast.
The surgical implications of estrophile protein estimations in carcinoma of the breast.
复制标题
乳腺癌中球粒蛋白估计的手术意义。
作者：
Walt Aj;A. Singhakowinta;Brooks Sc;A. Cortez
分析了161例既往未接受过添加剂或消融性激素治疗的患者的亲雌激素蛋白（ER）检测结果，47.2%的患者ER阳性，52.8%的患者ER阴性。共有37.5%的绝经前和50.8%的绝经后患者患有ER阳性肿瘤。在75名患者中观察到添加剂和消融性激素治疗的效果; ER阳性组的63.5%和ER阴性组的8.6%有反应，但ER阴性组的发病率被认为是虚假的高。ER阳性组的ER含量水平不影响反应程度。ER阴性组在发现肿瘤后的寿命较短，并且更容易发生显性内脏转移。在15例激素治疗（添加和/或消融）后进行ER测定的患者中，14例显示ER水平显著福尔斯下降，但这些与临床反应无关。在9例患者的肿瘤检测照射后的病变不含明显的ER。乳腺癌组织的ER测定被证明是一个有用的，但不完美的工具，在预测激素操作后的临床进展，但一些读数可能是虚假的低，由于不完善的测量技术，以前的外源性激素管理或激素消融，和以前的肿瘤照射。
Assays of estrophile protein (ER) in 161 patients with no previous additive or ablative hormonal therapy have been analyzed; 47.2 percent were ER positive; 52.8 percent ER negative. A total of 37.5 percent of premenopausal and 50.8 percent of postmenopausal patients had ER-positive tumors. The effects of additive and ablaive hormonal therapy were observed in 75 patients; 63.5 percent of the ER-positive group and 8.6 percent of the ER-negative group responded, but the incidence in the ER-negative group is thought to be spuriously high. The level of the ER content in the ER-positive group did not influence the degree of response. The ER-negative group had a shorter life span after discovery of the tumor and was more likely to develop dominant visceral metastases. Of 15 patients followed with sequential ER assays after hormonal therapy (additive and/or ablative), 14 demonstrated substantial falls in ER levels but these did not correlate with the clinical response. Tumor assayed in nine patients after irradiation of the lesion contained no demonstrable ER. ER assays of breast cancer tissue proved to be a useful but imperfect tool in predicting clinical progress following hormonal maneuvers but some readings may be spuriously low due to imperfect techniques of measurement, prior exogenous hormonal administration or hormonal ablation, and previous irradiation of the tumor.